Full Press Release Details
Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major
Calif. August 26, 2024 - LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"),
today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI)
and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer.
part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and Roche is providing
atezolizumab (Tecentriq , a PDL1 inhibitor) through the imCORE Network, a global academic-industry partnership that aims
to accelerate cancer immunotherapy research through institution-sponsored studies.
objective with this trial is to bring immunotherapy as an effective treatment option to approximately 85 percent of all colorectal cancer
patients, who thus far have not been responsive to traditional protocols," said Neeltje Steeghs, M.D., Ph.D., medical oncologist
van der Baan, LIXTE's Chief Executive Officer, said, "We are pleased to begin this important trial, which is being funded
by Roche. This is the second recent clinical trial combining LB-100 with immunotherapy that is funded by a major pharmaceutical company,
following the start of a clinical trial earlier this year with GSK for treatment of clear cell ovarian cancer."
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated
in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com),
LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology - activation lethality -
that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept
clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers. Additional information about LIXTE can be found
Statement Disclaimer
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing
development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal
costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain
compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied
by words such as "intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other comparable terminology.
Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have
been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected
or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general
are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission
at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
more information about LIXTE, Contact: info@lixte.com
Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Inc. Investor Relations pwinvestor@pondel.com
Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962